A Study on Behavioral and Psychological Symptoms of Dementia

This is an observational, prospective, multi-center study to obtain information about the symptoms and treatment received for patients with behavioral and psychological symptoms of dementia (BPSD). Patients must first meet eligibility criteria and sign informed consent. Patient treatment will be based upon investigator opinion. The following parameters will be assessed: patient's characteristics, Clinical Global Impression (CGI) score, Neuropsychiatric Inventory (NPI), and Minimal Mental Status Examination (MMSE). Each patient will be observed for 12 weeks. Medication dosing regimen will be flexible throughout the study and is based on patient response and investigator judgment. During the study observation period, all patients will attend clinic visits for the subsequent 12 weeks (visit 2 to 3) as is the usual clinical practice. Patients can visit clinics on additional dates as needed or by request. At the pre-planned clinic visits, CGI score, NPI, vital signs, reports of adverse events, drug information, and MMSE score (visit 3) will be recorded. This is an observational study and no study drug is administered.

Inclusion criteria

• Patients with the diagnosis of dementia according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) criteria
• Patients meet one of the following types of Dementia: Dementia of the Alzheimer's Type (AD), Vascular Dementia (VaD), Dementia of Lewy Body (DLB), Parkinson's Disease Dementia (PDD)
• Patients have one or more active symptoms of Behavioral and Psychological Symptoms of Dementia (BPSD) on Neuropsychiatric Inventory (NPI) and have not received treatment with antipsychotics, mood stabilizers, or antidepressants within 1 month prior to study entry
• Patients are with caregiver(s) who can give appropriate information about the patients and can assist with the assessment during the study
• Patients (or a legally acceptable representative) have signed the informed consent form

Exclusion criteria

• Patients with concurrent other primary major psychiatric disorders (such as Schizophrenia or Bipolar disorder)
• Patients with history of severe allergies or multiple adverse drug reactions
• Patients with history or current symptoms of tardive dyskinesia
• Patients with history of neuroleptic malignant syndrome (NMS)
• Patients who participated in a clinical trial of any investigational drug within 1 month (30 days) prior to study entry